Education Center

A First-Line Treatment Option for Patients with Advanced Renal Cell Carcinoma

This supplement is sponsored by Exelixis, Inc.

 

Click to Read.

In this supplement to Federal Practitioner , Dr. Sachdev Thomas reviews safety and efficacy results from a clinical trial in intermediate and poor risk patients with advanced renal cell carcinoma (RCC), the most common type of kidney cancer in the United States.

Topics Include:

  • Inpatient and outpatient data from the Veterans Health Administration
  • Efficacy results vs a standard of care treatment
  • Highlights from a trial which studied the treatment in patients with advanced RCC who received a prior anti-angiogenic therapy

About the Author
Sachdev Thomas, MD
Assistant Clinical Professor, Health Sciences
University of California San Francisco, Fresno
Fresno, CA

Click to Read.

CA-0948

Next Article: